SAS Output

21-OCT-2018 6:10

CANCER CONTROL ACCRUAL REPORT

The REPORT Procedure

Detailed and/or summarized report

Table 1

STUDY R
E
G
O
P
E
N
ARM TOTAL
REGS.
REGS.
LAST
12
Month
REGS.
LAST
6
Month
REGS.
LAST
3
Month
REGS.
LAST
30
DAYS
REGS.
LAST
7
DAYS
ADMIN
S1007-Breast,Adj,N1,Endocrine+/-Chemo 1 Y 1 Recurrence Score testing 9383 0 0 0 0 0 BREAST
        9383 0 0 0 0 0  
 
  2 Y 2 Chemo and Endocrine Therapy 2547 2 0 0 0 0  
      3 Endocrine Therapy Alone 2536 1 0 0 0 0  
        5083 3 0 0 0 0  
 
S1207-Brst,Adj,Endocrine+/-Everolimus 1 Y 1 Blinded drug + Endocrine 867 177 83 46 19 4 BREAST
      2 Blinded drug + Endocrine 866 166 75 33 7 2  
        1733 343 158 79 26 6  
 
S1316-Compar. Effectiv. Trial for MBO 1 Y 1 Randomization Surgery 7 4 2 2 2 1 SURV
      2 Randomization Non-surgical M 6 5 1 1 0 0  
      3 Patient Choice Surgery 50 14 5 4 1 0  
      4 Patient Choice Non-surgical M 100 23 0 0 0 0  
        163 46 8 7 3 1  
 
S1415CD-TrACER CSF Standing Order Intervention for FN 1 Y 1 Site assigned to Cohort 573 244 126 46 17 3 CCD
      2 Site randomized: Control 398 202 92 42 20 3  
      3 SiteRand Int Risk: CSF 697 432 177 78 29 10  
      4 SiteRand Int Risk: No CSF 557 352 168 89 33 7  
        2225 1230 563 255 99 23  
 
S1417CD-Colorectal, Cost Cohort Study 1 Y 1 Observation 325 205 95 44 19 4 CCD
        325 205 95 44 19 4  
 
S1418-Breast, Adj, TNBC, MK-3475 (Pembrolizumab) 1 Y 1 Tissue for PD-L1 testing 331 241 129 66 24 4 BREAST
        331 241 129 66 24 4  
 
  2 Y 2 Observation 142 104 50 26 9 2  
      3 MK-3475 (Pembrolizumab) 140 101 54 28 8 0  
        282 205 104 54 17 2  
 
S1501-Surv, Breast Stg IV, Card Tox w/ Carvedilol 1 Y 0 Screening 48 48 42 24 9 2 SURV
        48 48 42 24 9 2  
 
  2 Y 1 Carvedilol 8 8 6 4 1 0  
      2 No intervention 8 8 5 4 2 1  
      3 Observation 26 26 25 14 8 3  
        42 42 36 22 11 4  
 
S1602-Blad, HG NMIBC, TICE/Tokyo/Prime+Tokyo BCG 1 Y 1 TICE BCG 59 45 27 19 4 1 GU
      2 Tokyo-172 BCG 57 44 27 16 4 0  
      3 Prime + Tokyo-172 BCG 55 43 26 14 3 1  
        171 132 80 49 11 2  
 
S1703-Met Breast, STM-monitoring v Usual Care 1 Y 0 Screening 4 4 4 4 2 0 CCD
        4 4 4 4 2 0  
 
  2 Y   0 0 0 0 0 0  
        0 0 0 0 0 0  
 
S1802-Pros, Stg IV, SST +/- Surg/RT to Primary Tum 1 Y 0 Induction SST 7 7 7 7 7 0 GU
        7 7 7 7 7 0  
 
  2 Y 1 Standard Systemic Therapy Only 1 1 1 1 1 0  
      2 SST + Surgery/RT 1 1 1 1 1 0  
        2 2 2 2 2 0  
 
S0820-PACES: ColrecStg0-3 Blind DFMO/Sulindac 0 Y 0 Pre-Registration 503 95 14 7 3 1 PREV
        503 95 14 7 3 1  
 
  1 Y 1 Blinded drug 71 26 12 4 3 1  
      2 Blinded drug 36 0 0 0 0 0  
      3 Blinded drug 35 0 0 0 0 0  
      4 Blinded drug 74 26 12 5 2 0  
        216 52 24 9 5 1  
 

21-OCT-2018 6:10

CANCER CONTROL ACCRUAL REPORT

The REPORT Procedure

Detailed and/or summarized report

Table 1

Open Studies with No Registrations
S1703-Met Breast, STM-monitoring v Usual Care regtype: 2